- Home
- GLMD
as 04-25-2025 2:37pm EST
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
| Founded: | 2000 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.0M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 109.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.21 - $23.80 | Next Earning Date: | 05-29-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Galmed Pharmaceuticals Ltd. News
GLMD Breaking Stock News: Dive into GLMD Ticker-Specific Updates for Smart Investing
PR Newswire
8 days ago
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
PR Newswire
10 days ago
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
PR Newswire
15 days ago
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
PR Newswire
23 days ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
PR Newswire
a month ago
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Associated Press Finance
5 months ago
Galmed Pharmaceuticals: Q3 Earnings Snapshot
PR Newswire
7 months ago
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
PR Newswire
7 months ago
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Compare GLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLMD Galmed Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.